Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine vs Oxybutynin XL in Pediatric Overactive Bladder
NCT02327936Phase 3Completed
- Start
- Dec 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of fesoterodine in overactive bladder syndrome (OAB) (2 arms). Primary endpoint: Number of Participants with Adverse Events at 4 months. Started Dec 2014; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT02327936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327936.